Immune Escape Articles & Analysis
7 news found
NextPoint’s programs aim to deliver monotherapies for cancer patients without viable treatment options. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. ...
ByBayer AG
Airfinity predicts a potential ‘twindemic’ of COVID-19 and flu could overwhelm hospitals this winter. The analysis focuses on two potential scenarios, based on data from previous winter COVID-19 waves driven by the Alpha and Omicron BA.1 variants as well as historical flu admissions from 2017-2018, the last bad flu season, as another bad flu season is expected this year based on ...
Over the past decade, immunotherapy has become one of the mainstays of cancer treatment, thanks in large part to monoclonal antibodies targeting the immune checkpoint protein PD-1 or its major ligand PD-L1 (mAbs). Due to abnormal immune surveillance mediated by immune checkpoints, tumor cells develop immune ...
We believe that Zephyr’s technology is key to helping us identify disease-specific, shared antigens and neoantigens as targets - which can be combined and delivered using the AIM platform - in addition, it may also increase our knowledge of how cancers evolve with the potential to address immune escape mechanisms.” “NexImmune’s AIM ...
B.1.617.1 is defined by the spike amino acid changes G142D, E154K, L452R, E484Q, D614G, P681R, and Q1071H. The impact on the immune escape capacity of B.1.617 sublineages is expected, owing to RBD mutations L452R, T478K, and E484Q and their combination with NTD mutations and deletions, particularly in the case of B.1.617.2. ...
Our selective A2a receptor antagonist addresses a next-generation IO strategy to empower the human immune system by reversing the effects of high adenosine concentrations. ...
Global studies on Covid-19 have shown that the two strains have biological changes that would speed infection with an increased immune escape from previously reported strains. The World Health Organization (WHO) on September 21st further pointed out that BA.5 has accounted for 76.6% of global new cases, and BA.4 for 7.5%. ...
ByiXensor